Clinical trial
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
NCT00466752
Study timeline
Study start (unknown)2006-12-01Date precision: month
Registry last updated2017-11-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Adenocarcinoma of the Prostateunresolved
Stage II Prostate Cancerunresolved
Stage III Prostate Cancerunresolved
Interventions
sorafenib tosylateDRUG · verified · RxNorm: sorafenib tosylate
microarray analysisGENETIC
gene expression analysisGENETIC
needle biopsyPROCEDURE
therapeutic conventional surgeryPROCEDURE
western blottingGENETIC
RNA analysisGENETIC
Sponsors & collaborators
University of Washingtonlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00466752 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.